Assoc. Prof. RNDr. Jakub Hofman, Ph.D.

Education and training

Positions

Teaching activities

Research interests

• uncovering mechanisms of tumor drug resistance
• design of approaches for modulation of tumor drug resistance
• pharmacokinetic interactions of novel drug entities and their utilization for combating tumor drug resistance
• implementation of advanced primary ex vivo and in vivo lung and breast tumoral models
• transplacental pharmacokinetics of drugs – role of ABC transporters (past)
• gene delivery using nano-formulated cationic polymers and liposomes (past)

Grants received

Principal investigator 

• GAUK 114909/C – Study of interactions of CDK inhibitors with ABCG2 (BCRP) drug transporter, Grant Agency of Charles University
• GAČR 20-20414Y - Study on the role of novel targeted breast and lung anticancer drugs in the phenomenon of pharmacokinetic drug resistance, Czech Science Foundation

Co-investigator or mentor

• KAN200100801 – Bioactive biocompatible surfaces and novel nanostructured composites for applications for medicine and drug delivery, Grant Agency of the Academy of Sciences of the Czech Republic
• GAUK 137010/C – Localization and function of organic cation transporter 3 (OCT3) in the rat placenta, Grant Agency of Charles University
• GAUK 700912/C – Study of interactions of cyclin-dependent kinase inhibitors with ABCB1 drug efflux transporter, Grant Agency of Charles University
• GAČR 16-26849S - Interactions of protein kinase inhibitors with drug transporters and biotransformation enzymes; role in overcoming resistance in anticancer therapy, Czech Science Foundation
• GAUK 1568218/C - Interactions of novel anticancer drugs with ABC drug efflux transporters and cytochromes P450; their role in multidrug resistance, Grant Agency of Charles University
• GAUK 334120/C - The role of pharmacokinetic interactions of new targeted drugs in the modulation of efficacy of cytotoxic drugs in non-small cell lung carcinoma, Grant Agency of Charles University
• PRIMUS 20/MED/010 - Farmakokinetické mechanizmy lékové rezistence u akutní myeloidní leukémie, jejich ovlivnění a regulace
• START/MED/070 - Unraveling pharmacodynamic principles of acquired resistance to epidermal growth factor receptor inhibitors
• GAUK 102121/C - Implementation of ex vivo and in vivo lung tumor models for the evaluation of clinical value of dual drug resistance modulators
• INOMED - Pre-application research into innovative medicines and medical technologies, OP VVV programme, Ministry of Education, Youth and Sport of the Czech republic and EU funds
• NETPHARM - New Technologies for Translational Research in Pharmaceutical Sciences, OP JAK programme, Ministry of Education, Youth and Sport of the Czech republic and EU funds
• ONCOPHARM - Pre-application research of drugs for oncological diseases and for the prevention and treatment of serious complications caused by them, OP JAK programme, Ministry of Education, Youth and Sport of the Czech republic and EU funds

Memberships

• International Society for the Study of Xenobiotics (ISSX)
• Czech Society for Experimental and Clinical Pharmacology and Toxicology (ČSEKFT ČLS JEP)
• International Transmembrane Transporter Society (ITTS)
• European Association for Cancer Research (EACR)
• board member in Grant Agency of Charles University

Awards

• 2010 - finalist for the postdoctoral poster awards competition, 9th International ISSX Meeting, Istanbul, Turkey
• 2014 - trainee award, 17th International Workshop on the Enzymology and Molecular Biology of Carbonyl Metabolism, Skytop, PA, USA
• 2018 - co-author of best publication in Experimental Pharmacology section of competition organized by ČSEKFT ČLS JEP
• 2018 - co-author of best oral presentation in Young Pharmacologists section, 68. Česko-Slovenské farmakologické dny, Hradec Králové, Czech Republic

Publications

h-index = 16, 585 citations (excluding self-citations; 17th April 2025)

1. Hahnova Cygalova L., Hofman J., Ceckova M., Staud F.: Transplacental pharmacokinetics of glyburide, rhodamine 123, and BODIPY FL Prazosin: Effect of drug efflux transporters and lipid solubility. J Pharmacol Exp Ther 2009; 331 (3): 1118 – 25 (IF for 2009 = 4.309)
2. Piterkova J., Hofman J., Mieslerova B., Sedlarova M., Luhova L., Lebeda A., Petřivalský M.: Dual role of nitric oxide in Solanum spp.-Oidium neolycopersici interactions. Environ Exp Bot 2011; 74: 37 – 44 (IF for 2011 = 2.985)
3. Hofman J., Ahmadimoghaddam D., Hahnova L., Pavek P., Ceckova M., Staud F.: Olomoucine II and purvalanol A inhibit ABCG2 transporter in vitro and in situ and synergistically potentiate cytostatic effect of mitoxantrone. Pharmacol Res 2012; 65 (3): 312 – 9 (IF for 2012 = 4.346)
4. Ahmadimoghaddam D., Hofman J., Zemankova L., Nachtigal P., Dolezelova E., Cerveny L., Ceckova M., Micuda S., Staud F.: Synchronized activity of organic cation transporter 3 (Oct3/SLC22A3) and multidrug and toxin extrusion 1 (Mate 1/SLC47A1) transporter in transplacental passage of MPP+ in rat. Toxicol Sci 2012; 128 (2): 471 – 81 (IF for 2012 = 4.328)
5. Piterkova J., Luhova L., Hofman J., Tureckova V., Novak O., Petrivalsky M., Fellner M.: Nitric oxide is involved in light-specific responses of tomato during germination under normal and osmotic stress conditions. Ann Bot 2012; 110 (4): 767 - 76 (IF for 2012 = 3.449)
6. Hofman J., Buncek M., Haluza R., Streinz L., Ledvina M., Cigler P.: In vitro transfection mediated by dendrigraft poly(L-lysines): effect of structure and molecule size. Macromol Biosci 2013; 13 (2): 167 – 76 (IF for 2013 = 3.650)
7. Hofman J., Kučera R., Cihalova D., Klimes J., Ceckova M., Staud F.: Olomoucine II, but Not Purvalanol A, Is Transported by Breast Cancer Resistance Protein (ABCG2) and P-glycoprotein (ABCB1). PLoS One 2013; 8 (10): e75520 (IF for 2013 = 3.534)
8. Cihalova D., Hofman J., Ceckova M., Staud F.: Purvalanol A, olomoucine II and roscovitine inhibit ABCB1 transporter and synergistically potentiate cytotoxic effects of daunorubicin in vitro. PLoS One 2013; 8 (12): e83467 (IF for 2013 = 3.534)
9. Hofman J., Malcekova B., Skarka A., Novotna E., Wsol V.: Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3. Toxicol Appl Pharmacol 2014; 278 (3): 238 - 48 (IF for 2014 = 3.705)
10. Skarydova L., Hofman J., Chlebek J., Havrankova J., Kosanova K., Skarka A., Hostalkova A., Plucha T., Cahlikova L., Wsol V.: Isoquinoline alkaloids as a novel type of AKR1C3 inhibitors. J Steroid Biochem Mol Biol 2014; 143: 250 – 8 (IF for 2014 = 3.628)

11. Hofman J., Skarka A., Havrankova J., Wsol V.: Pharmacokinetic interactions of breast cancer chemotherapeutics with human doxorubicin reductases. Biochem Pharmacol 2015; 96 (3): 168 - 78 (IF for 2015 = 5.091)

12. Hofman J., Kučera R., Neumanova Z., Klimes J., Ceckova M., Staud F.: Placental passage of olomoucine II, but not purvalanol A, is affected by p-glycoprotein (ABCB1), breast cancer resistance protein (ABCG2) and multidrug resistance-associated proteins (ABCCs). Xenobiotica 2016; 46(5): 416-23 (IF for 2016 = 1.932).

13. Zemanova L., Hofman J., Novotna E., Musilek K., Lundova T., Havrankova J., Hostalkova A., Chlebek J., Cahlikova L., Wsol V.: Flavones Inhibit the Activity of AKR1B10, a Promising Therapeutic Target for Cancer Treatment. J Nat Prod 2015; 78 (11): 2666 - 74 (IF for 2015 = 3.662)

14. Hintzpeter J., Seliger J.M., Hofman J., Martin H.J., Wsol V., Maser E.: Inhibition of human anthracycline reductases by emodin - a possible remedy for anthracycline resistance. Toxicol Appl Pharmacol 2016; 293: 21-9 (IF for 2016 = 3.791)

15. Siroka J., Ceckova M., Urbanek L., Krystof V., Gucky T., Hofman J., Strnad M., Staud F.: LC-MS/MS method for determination of cyclin-dependent kinase inhibitors, BP-14 and BP-20, and its application in pharmacokinetic study in rat. J Chromatogr B Analyt Technol Biomed Life Sci 2018; 1089: 24-32 (IF for 2018 = 2.813)

16. Sorf A., Hofman J, Kucera R., Staud F., Ceckova M.: Ribociclib shows potential for pharmacokinetic drug-drug interactions being a substrate of ABCB1 and potent inhibitor of ABCB1, ABCG2 and CYP450 isoforms in vitro. Biochem Pharmacol 2018; 154: 10-7 (IF for 2018 = 4.825)

17. Novotna E., Büküm N., Hofman J., Flaxova M., Kouklikova E., Louvarova D., Wsol V.: Aldo-keto reductase 1C3 (AKR1C3): a missing piece of the puzzle in the dinaciclib interaction profile. Arch Toxicol 2018; 92: 2845-2857 (IF for 2018 = 5.741)

18. Novotna E., Büküm N., Hofman J., Flaxova M., Kouklikova E., Louvarova D., Wsol V.: Roscovitine and purvalanol A effectively reverse anthracycline resistance mediated by the activity of aldo-keto reductase 1C3 (AKR1C3). Biochem Pharmacol 2018; 156: 22-31 (IF for 2018 = 4.825)

19. Büküm N., Novotna E., Morell A., Hofman J., Wsol V.: Buparlisib is a novel inhibitor of daunorubicin reduction mediated by aldo-keto reductase 1C3. Chem Biol Interact 2019; 302: 101-7 (IF for 2019 = 3.723)

20. Sorf A., Novotna E., Hofman J., Morell A., Staud F., Wsol V., Ceckova M.: Cyclin-dependent kinase inhibitors AZD5438 and R547 show potential for enhancing efficacy of daunorubicin-based anticancer therapy: Interaction with carbonyl-reducing enzymes and ABC transporters. Biochem Pharmacol 2019; 163: 290-8 (IF for 2019 = 4.960)

21. Hofman J., Sorf A., Vagiannis D., Sucha S., Novotna E., Kammerer S., Küpper J-H., Ceckova M., Staud F.: Interactions of Alectinib with Human ATP-Binding Cassette Drug Efflux Transporters and Cytochrome P450 Biotransformation Enzymes: Effect on Pharmacokinetic Multidrug Resistance. Drug Metab Dispos 2019; 47(7): 699-709 (IF for 2019 = 3.231)
22. Hofman J., Sorf A., Vagiannis D., Sucha S., Kammerer S., Küpper J-H., Chen S., Guo L., Ceckova M., Staud F.: Brivanib Exhibits Potential for Pharmacokinetic Drug-Drug Interactions and the Modulation of Multidrug Resistance through the Inhibition of Human ABCG2 Drug Efflux Transporter and CYP450 Biotransformation Enzymes. Mol Pharmaceut 2019; 16(11): 4436-4450 (IF for 2019 = 4.321)
23. Vagiannis D., Novotna E., Skarka A., Kammerer S., Küpper J-H., Chen S., Guo L., Staud F., Hofman J.: Ensartinib (X-396) Effectively Modulates Pharmacokinetic Resistance Mediated by ABCB1 and ABCG2 Drug Efflux Transporters and CYP3A4 Biotransformation Enzyme. Cancers 2020; 12(4): E813 (IF for 2020 = 6.639)
24. Vagiannis D., Zhang Y., Novotna E., Morell A., Hofman J.: Entrectinib reverses cytostatic resistance through the inhibition of ABCB1 efflux transporter, but not the CYP3A4 drug-metabolizing enzyme. Biochem Pharmacol 2020; 178: 114061 (IF for 2020 = 5.858)
25. Novotna E., Morell A., Büküm N., Hofman J., Danielisová P., Wsól V.: Interactions of antileukemic drugs with daunorubicin reductases: could reductases affect the clinical efficacy of daunorubicin chemoregimens?. Arch Toxicol 2020; 94: 3059-3068 (IF for 2020 = 5.153)
26. Tavares T., Hofman J., Lekešová A., Zelazkova J., Wsol V.: Olaparib synergizes the anticancer activity of daunorubicin via interaction with AKR1C3. Cancers 2020; 12(11):3127 (IF for 2020 = 6.639)
27. Hofman J., Vagiannis D., Chen S., Guo L.: Roles of CYP3A4, CYP3A5 and CYP2C8 drug-metabolizing enzymes in cellular cytostatic resistance. Chem Biol Interact 2021; 340:109448 (IF for 2021 = 5.168)
28. Vagiannis D., Budagaga Y., Morell A., Zhang Y., Novotná E.,  Skarka A., Kammerer S., Küpper J-H., Hanke I., Rozkoš T., Hofman J.: Tepotinib Inhibits Several Drug Efflux Transporters and Biotransformation Enzymes: The Role in Drug-Drug Interactions and Targeting Cytostatic Resistance In Vitro and Ex Vivo. Int J Mol Sci 2021; 22(21):11936 (IF for 2021 = 6.208)
29. Sorf A., Vagiannis D., Fahda A., Hofman J., Ceckova M.: Dabrafenib inhibits ABCG2 and cytochrome P450 isoenzymes; potential implications for combination anticancer therapy. Toxicol Appl Pharmacol 2022; 434:115797 (IF for 2022/2023 = 3.8)
30. Vagiannis D., Zhang Y., Budagaga Y., Novotna E.,  Skarka A., Kammerer S., Küpper J-H., Hofman J.: Alisertib shows negligible potential for perpetrating pharmacokinetic drug-drug interactions on ABCB1, ABCG2 and cytochromes P450, but acts as dual-activity resistance modulator through the inhibition of ABCC1 transporter. Toxicol Appl Pharmacol 2022; 434:115823 (IF for 2022/2023 = 3.8)
31. Zhang Y., Vagiannis D., Budagaga Y., Sabet Z., Hanke I., Rozkoš T., Hofman J.: Sonidegib potentiates the cancer cells' sensitivity to cytostatic agents by functional inhibition of ABCB1 and ABCG2 in vitro and ex vivo. Biochem Pharmacol 2022; 199:115009 (IF for 2022/2023 = 5.8)
32. Morell A., Budagaga Y., Vagiannis D., Zhang Y., Laštovičková L., Novotná E., Haddad A., Haddad M., Portillo R., Hofman J., Wsól V.: Isocitrate dehydrogenase 2 inhibitor enasidenib synergizes daunorubicin cytotoxicity by targeting aldo-keto reductase 1C3 and ATP-binding cassette transporters. Arch Toxicol 2022; 96(12): 3265-3277 (IF for 2022/2023 = 6.1)
33. Čermáková L., Hofman J., Laštovičková L., Havlíčková L., Špringrová I., Novotná E., Wsól V: Bruton's Tyrosine Kinase Inhibitor Zanubrutinib Effectively Modulates Cancer Resistance by Inhibiting Anthracycline Metabolism and Efflux. Pharmaceutics 2022; 14(10): 1994 (IF for 2022/2023 = 5.4)

34. Sabet Z., Vagiannis D., Budagaga Y., Zhang Y., Novotná E., Hanke I., Rozkoš T., Hofman J.: Talazoparib Does Not Interact with ABCB1 Transporter or Cytochrome P450s, but Modulates Multidrug Resistance Mediated by ABCC1 and ABCG2: An in Vitro and Ex Vivo Study. Int J Mol Sci 2022; 23(22): 14338 (IF for 2022/2023 = 5.6)

35. Zhang Y., Vagiannis D., Budagaga Y., Sabet Z., Hanke I., Rozkoš T., Hofman J.: Encorafenib Acts as a Dual-Activity Chemosensitizer through Its Inhibitory Effect on ABCC1 Transporter In Vitro and Ex Vivo. Pharmaceutics 2022; 14(12): 2595 (IF for 2022/2023 = 5.4)

36. Budagaga Y., Sabet Z., Zhang Y., Novotná E., Hanke I., Rozkoš T., Hofman J.: Tazemetostat synergistically combats multidrug resistance by the unique triple inhibition of ABCB1, ABCC1, and ABCG2 efflux transporters in vitro and ex vivo. Biochem Pharmacol 2023;216:115769 (IF for 2022/2023 = 5.8)